Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine

Egatz-Gómez, Ana; Wang, Ceming; Klacsmann, Flora; Pan, Zehao; Marczak, Steven P.; Wang, Yunshan; Sun, Gongchen; Senapati, Satyajyoti; Chang, Hsueh‐Chia

doi:10.1063/1.4948525

Cited by 44 publications

(35 citation statements)

References 181 publications

(230 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are commercially available microfluidic systems that just incorporated the separation and extraction of the exosomes, but the readout is performed externally, such as the ExoChip [65], nPLEX [79], iMER [80], ExoSearch [81], Nano-IMEX [82], and µMED [83]. Besides, other microfluidic systems were explored based on size and other intrinsic properties [84][85][86][87][88][89][90][91].…”

Section: Platforms Based On Exosomes Analysismentioning

confidence: 99%

Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer

Sierra

Marrugo-Ramírez

Rodriguez-Trujíllo

et al. 2020

Sensors

View full text Add to dashboard Cite

Cancer represents one of the conditions with the most causes of death worldwide. Common methods for its diagnosis are based on tissue biopsies—the extraction of tissue from the primary tumor, which is used for its histological analysis. However, this technique represents a risk for the patient, along with being expensive and time-consuming and so it cannot be frequently used to follow the progress of the disease. Liquid biopsy is a new cancer diagnostic alternative, which allows the analysis of the molecular information of the solid tumors via a body fluid draw. This fluid-based diagnostic method displays relevant advantages, including its minimal invasiveness, lower risk, use as often as required, it can be analyzed with the use of microfluidic-based platforms with low consumption of reagent, and it does not require specialized personnel and expensive equipment for the diagnosis. In recent years, the integration of sensors in microfluidics lab-on-a-chip devices was performed for liquid biopsies applications, granting significant advantages in the separation and detection of circulating tumor nucleic acids (ctNAs), circulating tumor cells (CTCs) and exosomes. The improvements in isolation and detection technologies offer increasingly sensitive and selective equipment’s, and the integration in microfluidic devices provides a better characterization and analysis of these biomarkers. These fully integrated systems will facilitate the generation of fully automatized platforms at low-cost for compact cancer diagnosis systems at an early stage and for the prediction and prognosis of cancer treatment through the biomarkers for personalized tumor analysis.

show abstract

Section: Platforms Based On Exosomes Analysismentioning

confidence: 99%

Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer

Sierra

Marrugo-Ramírez

Rodriguez-Trujíllo

et al. 2020

Sensors

View full text Add to dashboard Cite

show abstract

“…These typically use a modification of polymerase chain reaction (PCR), a procedure that uses temperature cycling to amplify DNA based upon a template sequence[31], [112]. This process allows for amplification of the number of DNA molecules, combating the problem of extremely low molecule numbers of circulating nucleic acids in blood.…”

Section: Technologies For Capture Detection and Analysis Of Circulamentioning

confidence: 99%

Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis

Tadimety

Closson

et al. 2018

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Liquid biopsy, as a minimally invasive method of gleaning insight into the dynamics of diseases through a patient fluid sample, has been growing in popularity for cancer diagnosis, prognosis, and monitoring. While many technologies have been developed and validated in research laboratories, there has also been a push to expand these technologies into other clinical settings and as point of-care devices. In this review we discuss and evaluate microchip-based technologies for circulating tumor cell (CTC), exosome, and circulating tumor nucleic acid (ctNA) capture, detection, and analysis. Such integrated systems streamline otherwise multiple-step, manual operations to get a sample-to-answer quantitation. In addition, analysis of disease biomarkers is suited to point of care settings because of ease of use, low consumption of sample and reagents, and high throughput. We also cover the basics of biomarkers and their detection in biological fluid samples suitable for liquid biopsy on-chip. We focus on emerging technologies that process a small patient sample with high spatial-temporal resolution and derive clinically meaningful results through on-chip biomarker sensing and downstream molecular analysis in a simple workflow. This critical review is meant as a resource for those interested in developing technologies for capture, detection, and analysis platforms for liquid biopsy in a variety of settings.

show abstract

“…A recent study used the phenomenon of conformational change of stem-looped aptamers to specifically capture target miR and amplify the detection signal by 50-fold [ 144 ]. The current standards for miR profiling like RT-PCR and microarray technologies are lab-bound and suffer from normalization issues that do not allow for cross-reference [ 145 ]. Although portable PCR units are now available, the extensive pretreatment for miR reverse-transcription has become a major bottleneck for low-resource applications.…”

Section: Nucleic Acid-based Screening Toolsmentioning

confidence: 99%

Current Technologies and Recent Developments for Screening of HPV-Associated Cervical and Oropharyngeal Cancers

Shah

Senapati

Klacsmann³

et al. 2016

Cancers

Self Cite

View full text Add to dashboard Cite

Mucosal infection by the human papillomavirus (HPV) is responsible for a growing number of malignancies, predominantly represented by cervical cancer and oropharyngeal squamous cell carcinoma. Because of the prevalence of the virus, persistence of infection, and long latency period, novel and low-cost methods are needed for effective population level screening and monitoring. We review established methods for screening of cervical and oral cancer as well as commercially-available techniques for detection of HPV DNA. We then describe the ongoing development of microfluidic nucleic acid-based biosensors to evaluate circulating host microRNAs that are produced in response to an oncogenic HPV infection. The goal is to develop an ideal screening platform that is low-cost, portable, and easy to use, with appropriate signal stability, sensitivity and specificity. Advances in technologies for sample lysis, pre-treatment and concentration, and multiplexed nucleic acid detection are provided. Continued development of these devices provides opportunities for cancer screening in low resource settings, for point-of-care diagnostics and self-screening, and for monitoring response to vaccination or surgical treatment.

show abstract

Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine

Cited by 44 publications

References 181 publications

Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer

Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer

Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis

Current Technologies and Recent Developments for Screening of HPV-Associated Cervical and Oropharyngeal Cancers

Contact Info

Product

Resources

About